Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
NCT ID: NCT04555161
Last Updated: 2025-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2021-03-15
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Assessment of the Aria CV System in Patients With WHO Groups 2 and 3 Pulmonary Hypertension
NCT05001711
Assessmet of Patients With PAH Right Ventricular Volume
NCT01557582
Rivet PVS Therapy in Group 2 PH-HFpEF
NCT05205265
Safety and Efficacy Study of the BioVentrix PliCath HF System
NCT01568164
BiVACOR® Total Artificial Heart Early Feasibility Study
NCT06174103
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will be conducted in a maximum of 20 centers in the United States and up to 30 patients will receive implants.
Patients will be evaluated at each of the following time intervals: pre-operative, implant procedure, 7-day (or discharge if earlier), and 1-, 2-, 3-, 4-, 6-, 9-, 12-, 15-, 18-, 21-, and 24-months post index procedure. The Aria CV PH System will be assessed at each follow-up visit. The duration of the study is anticipated to last about 2 years for each patient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aria CV Pulmonary Hypertension System
Treatment with the Aria CV Pulmonary Hypertension System
Aria CV Pulmonary Hypertension System
The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aria CV Pulmonary Hypertension System
The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Mean pulmonary artery pressure (mPAP) \> 25mmHg.
3. Right heart dysfunction as evidence by at least one of the following:
1. Tricuspid Annulus Plan Systolic Excursion (TAPSE) ≤ 16mm
2. RV Fractional area change \< 35%
3. RV systolic velocity \< 11.5 cm/s
4. RV free wall strain \< 18%
5. Lateral tricuspid annulus peak systolic velocity (S') \< 9cm/s
4. Pulmonary compliance (C) \< 3.0 ml/mmHg
5. Current assessment of WHO FC III or ambulatory IV
6. Main pulmonary artery (MPA) diameter and anatomy suitable for placement of the device as defined in the Instructions For Use (IFU) and as assessed by multi-slice computed tomography (MSCT).
7. Subject is deemed appropriate for Aria CV device by the Subject Care Team at the investigation site and approved by the Eligibility Review Committee (ERC).
8. The subject has agreed to participate in the study by signing the study specific informed consent form.
9. The subject agrees to abide by device related travel restrictions.
10. Pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg
11. Pulmonary vascular resistance (PVR) \> 3 Woods Units (WU)
12. The subject remains symptomatic despite being on a stable drug regimen of PH specific medication(s) appropriate for their PH classification for at least 90 days prior to planned index procedure.
10\. Previous diagnosis of heart failure with preserved ejection fraction (HFpEF) (ejection fraction ≥ 50%) 11. PCWP \> 15 mmHg 12. PVR \> 3 WU
10\. Previous diagnosis of lung disease, including but not limited to chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) including idiopathic pulmonary fibrosis (IPF) or combined emphysema with fibrosis.
11\. PCWP ≤ 15mmHg 12. PVR \>4 WU
Exclusion Criteria
2. Recent clinical event(s) of any of the following:
1. Myocardial infarction or stroke within 6 months prior to the index procedure;
2. Sustained tachyarrhythmia (documented heart rate \>110/min) within 2 months prior to the index procedure;
3. Uncontrolled, chronic atrial fibrillation.
3. Pre-existing or requirement of emergent surgery/ intervention, or implantation of prosthetic cardiac device that, in the opinion of the investigator, may interfere with Aria CV PH System placement or function.
4. Any of the following medical history or comorbidities:
a. History of endocarditis; b. History of unprovoked Pulmonary Embolism; c. Current renal insufficiency as demonstrated by an eGFR \< 30 mL/min/1.73 m2 or end stage renal disease requiring chronic dialysis; d. Current diagnosis of scleroderma associated with: i. Any history of GI bleeding or receiving iron infusions within 2 years prior to enrollment; ii. Significant skin involvement that could compromise daily activities or the ability to receive IV medications, or sclerodactyly that causes surface ulcerations, digital ulcerations, or ulcerating calcinosis lesions.
e. History of receiving immunosuppressant therapy as follows: i. Excluded if receiving Mycophenolate mofetil within 30 days prior to enrollment, or Rituximab within 6 months prior to enrollment, or currently receiving Prednisone at a dose \> 12 mg per day at time of enrollment; ii. Excluded if any immunosuppressant other than Mycophenolate mofetil, Rituximab or Prednisone, per above.
e. Current pulmonary veno-occlusive disease (PVOD); f. Current pulmonary capillary hemangiomatosis (PCH); g. History of clinically significant patent foramen ovale (PFO) or other inter-atrial or inter-ventricular shunt; h. History of gastric antral vascular ectasia (GAVE), gastrointestinal or intracranial bleeding which, in the opinion of the investigator, will predispose subject to major bleeding events following Aria CV device placement and warfarin anticoagulation regimen; i. Active infection requiring antibiotic therapy within two (2) weeks of procedure; j. Blood dyscrasias that may, in the opinion of investigator(s), expose subject to unacceptable procedural risks such as severe or worsening leukopenia, anemia, thrombocytopenia, untreated iron deficiency or history of bleeding diathesis or coagulopathy.
5. Anatomy is not suitable for placement of Aria CV device.
6. Right heart valve regurgitation as follows:
1. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation;
2. Severe (Grade 4) tricuspid valve regurgitation.
7. Hypersensitivity or contraindication to:
1. Required medications (e.g., contrast agents, warfarin, heparin) which cannot be adequately managed;
2. Materials in device including polyurethane, silicone, nickel, and titanium.
8. Ineligible for or refuses blood transfusion.
9. Pregnant, nursing or is planning to become pregnant in the next two years.
10. Life expectancy of less than two years.
11. Currently participating in or planning to participate in other investigational study that may interfere with the outcome of this study.
12. For subject on supplemental oxygen therapy - Subject adheres to the treatment regimen that in the opinion of the physician does not increase subject's safety.
13. Previous diagnosis of cardiac amyloidosis.
N/A
1. Previous diagnosis of idiopathic hypertrophic subaortic stenosis (IHSS, also known as hypertrophic obstructive cardiomyopathy - HOCM).
2. Untreated severe aortic or mitral stenosis
3. Diagnosis of heart failure with reduced ejection fraction (HFrEF)
4. Previous diagnosis of nonobstructive hypertrophic cardiomyopathy.
N/A
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aria CV, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ashwin Ravichandran, M.D.
Role: PRINCIPAL_INVESTIGATOR
Ascension Health
Jim White, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California - San Diego
La Jolla, California, United States
University of California-Los Angeles
Los Angeles, California, United States
St. Vincent Health
Indianapolis, Indiana, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Cornell University
New York, New York, United States
University of Rochester
New York, New York, United States
The Christ Hospital
Cincinnati, Ohio, United States
Ohio Health
Columbus, Ohio, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Aurora St Luke's Medical Center
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
VP of Clinical
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Vollmers K, Scandurra J, Woolley JR, Giridharan GA, Rothman AMK, Pritzker M, Weir EK, Gerges C, Lang I. Development of a Novel, Pulmonary Endovascular Device to Treat Patients With Pulmonary Hypertension. Pulm Circ. 2025 Jul 29;15(3):e70131. doi: 10.1002/pul2.70131. eCollection 2025 Jul.
Related Links
Access external resources that provide additional context or updates about the study.
Information about the Aria CV Pulmonary Hypertension System
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASPIREPH202001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.